Official UK procurement notice
Advance Purchase Agreement · UK public procurement notice
Authority: Business Energy and Industrial Strategy
What is being bought
Published requirement descriptionProcurement of the Covid-19 Adjuvanted Pandemic Vaccine.
CPV: Vaccines
The lotProcurement structure
single lot · no lot value publishedLot #1Procurement of the Covid-19 Adjuvanted Pandemic VaccineAwarded
Procurement of the Covid-19 Adjuvanted Pandemic Vaccine. Additional information: Contract value is being withheld due to commercial sensitivity (PCR 2015 Reg 50(6)(b) and (c) and FOIA 2000 Section 43). Publication may enable competitors to calculate cost per dose. This will commercially prejudice:
(i) the supplier in its negotiations with other national governments; and
(ii) the contracting authority in negotiations with other vaccine vendors. It may also impact fair competition between vaccine vendors.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 20 Oct 2021, 16:33 BST
- Last source update
- 20 Oct 2021, 16:33 BST
- Authority reference
2611/09/2020- FTS notice number
2021/S 000-026293- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-02ee22Find a Tender
- Why no open competition
The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons; Additional deliveries by the original supplier ordered under the strict conditions stated in the directive
- Published justification
The award of the contract to Aventis Pharma and GSK is strictly necessary due to absence of competition for technical reasons. Regulation 32 (b)(ii).
Furthermore, this Advance Purchase Agreement is the execution of the previous Capacity Reservation Agreement (Please see linked notice)
Publisher note: Additional information: contract end date is being withheld on grounds that release would be contrary to public interest (Reg 50(6)(a)) and commercial sensitivity (Reg 50(6)(b) and (c)). The date is variable based on production and delivery. Given significant challenges to overcome, the end date may set unrealistic expectation for the public/market. Also, given significant competition to bring to the market a successful vaccine, provision of the contract term is valuable information to competitors that may impact negotiations/future competition.
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Aventis Pharma Ltd Trading As Sanofi, GlaxoSmithKline Biologicals S.Ajoint award | £1 † | — | Awarded |
Contracts
Advance Purchase Agreement · Aventis Pharma Ltd Trading As Sanofi, GlaxoSmithKline Biologicals S.A
- Signed
- 20 Sept 2021
- Value
- £1
- Status
- active
Bid statistics published by the authority
| Bids | SME | VCSE | Valid bid range |
|---|---|---|---|
| 1bids | — | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Department of Business, Energy and Industrial StrategyReview body
Bidders & participating suppliers
2 commercial parties on the notice- Aventis Pharma LtdAwarded supplier
- GlaxoSmithKline Biologicals S.AAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.